Maintenance immunosuppression in myasthenia gravis
- PMID: 27653912
- DOI: 10.1016/j.jns.2016.08.057
Maintenance immunosuppression in myasthenia gravis
Abstract
Therapies for myasthenia gravis (MG) include symptomatic and immunosuppressive treatment. Options for immunosuppression include corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, methotrexate, rituximab, cyclophosphamide, intravenous immunoglobulin, plasmapheresis, and thymectomy. The practical aspects of long-term immunosuppressive therapy in MG will be critically reviewed in this article. Treatment for ocular and generalized myasthenia gravis will be discussed. Application of these therapies needs to be considered in conjunction with their efficacy, disease subtypes and severity, and patient co-morbidities.
Keywords: Corticosteroid; Immunosuppression; Intravenous immunoglobulin; Myasthenia gravis; Thymectomy.
Copyright © 2016 Elsevier B.V. All rights reserved.
Similar articles
-
Maintenance immunosuppression in myasthenia gravis, an update.J Neurol Sci. 2020 Mar 15;410:116648. doi: 10.1016/j.jns.2019.116648. Epub 2019 Dec 26. J Neurol Sci. 2020. PMID: 31901719 Review.
-
Therapeutic options in autoimmune myasthenia gravis.Autoimmun Rev. 2007 Jun;6(6):373-8. doi: 10.1016/j.autrev.2007.01.001. Epub 2007 Jan 30. Autoimmun Rev. 2007. PMID: 17537383 Review.
-
Myasthenia gravis: options and timing of immunomodulatory treatment.BioDrugs. 2001;15(3):173-83. doi: 10.2165/00063030-200115030-00004. BioDrugs. 2001. PMID: 11437683 Review.
-
[Therapeutic strategy in myasthenia gravis].Rev Neurol (Paris). 2009 Feb;165(2):149-54. doi: 10.1016/j.neurol.2009.01.005. Rev Neurol (Paris). 2009. PMID: 19233080 Review. French.
-
Immunosuppressive therapies in myasthenia gravis.Autoimmunity. 2010 Aug;43(5-6):428-35. doi: 10.3109/08916930903518107. Autoimmunity. 2010. PMID: 20166870 Review.
Cited by
-
A critical reflection on our first patient presenting with Anti-Nmethyl- D-aspartate receptor encephalitis.Neurol Int. 2019 Sep 18;11(3):8253. doi: 10.4081/ni.2019.8253. eCollection 2019 Sep 18. Neurol Int. 2019. PMID: 31579162 Free PMC article.
-
Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.Handb Exp Pharmacol. 2022;272:245-265. doi: 10.1007/164_2021_545. Handb Exp Pharmacol. 2022. PMID: 34595582
-
Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.Neurology. 2023 Feb 14;100(7):e671-e682. doi: 10.1212/WNL.0000000000201501. Epub 2022 Oct 21. Neurology. 2023. PMID: 36270895 Free PMC article. Clinical Trial.
-
Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis.Ther Adv Neurol Disord. 2019 Jul 17;12:1756286419864497. doi: 10.1177/1756286419864497. eCollection 2019. Ther Adv Neurol Disord. 2019. PMID: 31360225 Free PMC article.
-
Chinese Herbal Medicine for Myasthenia Gravis: A Systematic Review and Meta-Analysis.Front Pharmacol. 2018 Aug 30;9:969. doi: 10.3389/fphar.2018.00969. eCollection 2018. Front Pharmacol. 2018. PMID: 30214409 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical